Salipro Biotech publishes research in Scientific Reports on structure-function studies for membrane proteins in collaboration with AstraZeneca
2023-03-28
STOCKHOLM, March 28, 2023 /PRNewswire/ -- Salipro Biotech today announces the publication of results from a collaboration with AstraZeneca. The study describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for challenging drug targets. For this study, the teams leveraged GeneArt Gene-to-Protein Services, part of Thermo Fisher Scientific, for protein production with structure determination support from Thermo Fisher. The results were published on January 25th, 2023 and can be accessed at https://rdcu.be/c4cDp.
The scientists extracted and purified functional membrane proteins directly from cells using the membrane protein PANX1 as a case study. PANX1 is associated with various pathologies, including inflammation, pain, ischemia, and epilepsy. Exploration of PANX1 as a potential therapeutic target for novel therapeutics has however been limited due to overall lack of biophysical studies using isolated systems.
"Analyzing membrane proteins using SPR can pose a challenge due to the inherent instability of these drug targets and the difficulty in immobilizing enough functional membrane protein on the biosensor surface to ensure a measurable binding signal. By employing this innovative technique, we were able to confirm target engagement and measure the binding affinities of various pharmacological agents that are known to inhibit PANX1 activity." commented Stefan Geschwindner, Director of Biophysics, AstraZeneca.
"These results provide the basis for further investigations of novel PANX1 binders, leading to the development of more potent and specific compounds to further probe the biology of PANX1 and its potential as a therapeutic target. The novel methodology presented here accelerates the purification of membrane proteins that are ready to generate high-resolution cryo-EM structures, without the need for laborious and time-consuming detergent screenings, protein engineering or inefficient screening of alternative scaffolding setups." said Robin Löving, CSO of Salipro Biotech.
"We are excited to see the synergies of our collaboration come together, enabling the first structure-function studies of this drug target and laying the groundwork for future investigations of novel PANX1 binders." said Jens Frauenfeld, CEO of Salipro Biotech. "Once again we demonstrate that combining the strengths of complementary technologies indeed streamlines the process of discovering new therapeutic ligands and accelerates the development of new drugs."
Press contact:
Maria Lisa Knudsen
Business Development Director
+46 (0)72 939 5018
maria.knudsen@salipro.com
Logo: https://mma.prnewswire.com/media/2041077/Salipro_Logo.jpg
SOURCE Salipro
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。